Back to top
more

Labcorp Holdings Inc. (LH)

(Delayed Data from NYSE)

$259.96 USD

259.96
566,751

-0.89 (-0.34%)

Updated Aug 7, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable

by Zacks Equity Research

Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.

Zacks Equity Research

SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System

by Zacks Equity Research

SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.

Zacks Equity Research

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.

Zacks Equity Research

Here's Why You Should Retain Abbott (ABT) Stock For Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.

Zacks Equity Research

Bio Rad (BIO) Grows Internationally on New Product Launches

by Zacks Equity Research

Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.

Zacks Equity Research

CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies

by Zacks Equity Research

CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.

Zacks Equity Research

Has LabCorp (LH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.

Zacks Equity Research

Smith+Nephew (SNN) Rolls Out Robotic Assisted Surgical System

by Zacks Equity Research

Smith+Nephew's (SNN) CORI system enables each patient to have a knee replacement that is shape-matched and aligned to their specific anatomy.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

by Zacks Equity Research

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Zacks Equity Research

Illumina's (ILMN) New Alliance to Accelerate Genomics in China

by Zacks Equity Research

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Zacks Equity Research

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Zacks Equity Research

Veeva Systems (VEEV) Digital Tools Boost Patient Engagement

by Zacks Equity Research

Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.

Zacks Equity Research

LH vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LH vs. COO: Which Stock Is the Better Value Option?

Zacks Equity Research

Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

Zacks Equity Research

CVS Health's (CVS) New Measures to Boost Omnichannel Health

by Zacks Equity Research

CVS Health's (CVS) new measures will support its strategy of making health care more affordable, accessible and convenient for consumers.

Zacks Equity Research

LabCorp (LH) to Expand Nonclinical Development With New Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.

Zacks Equity Research

Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic

by Zacks Equity Research

Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.

Zacks Equity Research

Thermo Fisher (TMO) New Facility to Advance Lab Products Supply

by Zacks Equity Research

Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.

Zacks Equity Research

Bruker (BRKR) Advances in Proteomics Workflow With New Pacts

by Zacks Equity Research

Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.

Zacks Equity Research

Illumina (ILMN) iHope Genetic Health Program Expands WGS Access

by Zacks Equity Research

Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.

Zacks Equity Research

Abbott (ABT) Introduces New Next-Generation Infant Formula

by Zacks Equity Research

Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.

Zacks Equity Research

SmileDirectClub (SDC) Introduces Treatment Planning Software

by Zacks Equity Research

SmileDirectClub's (SDC) SmileOS will enable its affiliated network of state-licensed doctors to treat more patients, better predict tooth movements and visualize patients' treatment.

Zacks Equity Research

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.